Amphastar Pharmaceuticals, Inc. AMPH
26.13
(0.14)
(0.53%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 15.0×
Follow AMPH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 10.30% | 10.39% | 12.90% | 14.84% |
+8 more TTM periods Free account |
|
| 4.68% | 4.84% | 6.12% | 6.95% | ||
ROIC |
6.57% | 6.69% | 7.88% | 8.46% | |
Return on Tangible Assets |
11.49% | 10.20% | 12.44% | 15.03% | |
Average Days of Receivables |
73.74 | 79.76 | 81.49 | 75.13 | |
Free Cash Flow per Share |
3.50 | 2.98 | 2.54 | 2.39 | |
Free Cash Flow |
152.89 | 135.19 | 118.83 | 110.85 | |
Capital Expenditures |
(31.72) | (33.69) | (37.28) | (41.42) | |
Piotroski F-Score |
4.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
11.04% | 10.06% | 9.27% | 9.15% | |
Accounts Receivable Turnover |
5.18 | 4.76 | 4.82 | 4.92 | |
Accounts Payable Turnover |
1.83 | 2.31 | 2.38 | 2.13 | |
Inventory Turnover |
2.06 | 2.13 | 2.20 | 2.32 | |
Average Days of Payables |
240.24 | 146.89 | 148.83 | 190.18 | |
Days of Inventory on Hand |
171.94 | 163.73 | 177.46 | 185.29 | |
Tax Rate |
(0.23) | (0.23) | (0.21) | (0.18) | |
Research and Development Expense of Revenue |
12.95% | 12.84% | 11.92% | 11.15% | |
Selling, General and Administrative Expense of Revenue |
19.08% | 18.31% | 18.03% | 17.48% | |
Share Based Compensation of Revenue |
3.95% | 3.91% | 3.79% | 3.69% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.35 | 2.13 | 1.59 | 1.36 | |
Depreciation/Fixed assets |
0.19 | 0.20 | 0.19 | 0.19 | |
Capex/Depreciation |
(0.52) | (0.55) | (0.62) | (0.70) | |
Revenue per Share |
16.73 | 15.90 | 15.40 | 15.56 | |
Operating CF per Share |
4.23 | 3.73 | 3.34 | 3.28 | |
Capex per Share |
(0.73) | (0.74) | (0.80) | (0.89) | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.06 | |
Net Profit Margin |
10.76% | 11.00% | 13.63% | 15.43% |
Columns are period end dates